These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
605 related articles for article (PubMed ID: 10391672)
1. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine. Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672 [TBL] [Abstract][Full Text] [Related]
2. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
6. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
8. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B; Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176 [TBL] [Abstract][Full Text] [Related]
9. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538 [TBL] [Abstract][Full Text] [Related]
10. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272 [TBL] [Abstract][Full Text] [Related]
12. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103 [TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565 [TBL] [Abstract][Full Text] [Related]
14. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023 [TBL] [Abstract][Full Text] [Related]
15. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF; HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246 [TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928 [TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062 [TBL] [Abstract][Full Text] [Related]